Lixin Certified Public Accountants (Special General Partnership)
Response to the "Inquiry Letter Regarding the Cash-Based Major Asset Purchase by Wuhan Mindray Bio-Medical Electronics Co., Ltd."
BDO Letter No. ZE065 [2026]
Shenzhen Stock Exchange:
We have received your "Inquiry Letter Regarding the Cash-Based Major Asset Purchase by Wuhan Mindray Bio-Medical Electronics Co., Ltd." (Merger and Restructuring Inquiry Letter [2026] No. 9, hereinafter referred to as the "Inquiry Letter") issued on July 10, 2026, concerning the Major Asset Purchase Report (Draft) of Wuhan Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as "Mindray Bio-Medical," the "Listed Company," or the "Company"). In accordance with the requirements of the Inquiry Letter, Lixin Certified Public Accountants (Special General Partnership) (hereinafter referred to as "this Firm" or "the Accountant"), as the accountant for this major asset restructuring project, has conducted a diligent review of the issues requiring explanation or opinion from the accountant and hereby provides the following response:
Explanation regarding the interpretation, format, and supplementary disclosure of the response content:
-
Unless otherwise specified, the abbreviations used in this response report are the same as those defined in the "Major Asset Purchase Report of Wuhan Mindray Bio-Medical Electronics Co., Ltd." (Revised Draft). All figures in this document are rounded to two decimal places. The sum of the individual figures may differ slightly from the total due to rounding during the calculation process.
-
The financial data for the second quarter of 2026 involved in this response document are unaudited.
-
In this response, the target company's customers are referred to as "Customer 1, 2, 3..."
-
The fonts used in this response have the following meanings:
| Question listed in the Inquiry Letter | Bold | | Response to the questions in the Inquiry Letter | Songti | | Revisions and supplements to this inquiry response | Bold KaiTi |